Jouali Farah, Laarabi Fatima-Zahra, Marchoudi Nabila, Ratbi Ilham, Elalaoui Siham Chafai, Rhaissi Houria, Fekkak Jamal, Sefiani Abdelaziz
Anoual Laboratory of Radio-Immuno Analysis, Casablanca 20360, Morocco; Laboratory of Pathophysiology and Molecular Genetics, Ben M'Sik Faculty of Science, Casablanca 7955, Morocco.
Department of Medical Genetics, National Institute of Health, Rabat 769, Morocco.
Oncol Lett. 2016 Aug;12(2):1192-1196. doi: 10.3892/ol.2016.4739. Epub 2016 Jun 16.
At present, breast cancer is the most common type of cancer in females. The majority of cases are sporadic, but 5-10% are due to an inherited predisposition to develop breast and ovarian cancers, which are transmitted as an autosomal dominant form with incomplete penetrance. The beneficial effects of clinical genetic testing, including next generation sequencing (NGS) for mutations, is major; in particular, it benefits the care of patients and the counseling of relatives that are at risk of breast cancer, in order to reduce breast cancer mortality. genetic testing was performed in 15 patients with breast cancer and a family with positivity for the heterozygous c.6428C>A mutation of the gene. Informed consent was obtained from all the subjects. Genomic DNAs were extracted and the NGS for genes was performed using the Ion Torrent Personal Genome Machine (PGM) with a 316 chip. The reads were aligned with the human reference HG19 genome to elucidate variants in the and genes. Mutations detected by the PGM platform were confirmed by target direct Sanger sequencing on a second patient DNA sample. In total, 4 variants were identified in 6 families by NGS. Of these, 3 mutations had been previously reported: c.2126insA of , and c.1310_1313delAAGA and c.7235insG of . The fourth variant, c.3453delT in , has, to the best of our knowledge, never been previously reported. The present study is the first to apply NGS of the and genes to a Moroccan population, prompting additional investigation into local founder mutations and variant characteristics in the region. The variants with no clear clinical significance may present a diagnostic challenge when performing targeted resequencing. These results confirm that an NGS approach based on Ampliseq libraries and PGM sequencing is a highly efficient, speedy and high-throughput mutation detection method, which may be preferable in lower income countries.
目前,乳腺癌是女性中最常见的癌症类型。大多数病例是散发性的,但5%-10%是由于遗传易感性导致乳腺癌和卵巢癌的发生,其以常染色体显性形式遗传且具有不完全外显率。临床基因检测的益处很大,包括用于检测突变的新一代测序(NGS);特别是,它有利于乳腺癌患者的护理以及对有乳腺癌风险亲属的咨询,以降低乳腺癌死亡率。对15例乳腺癌患者以及一个携带该基因杂合c.6428C>A突变呈阳性的家族进行了基因检测。所有受试者均获得了知情同意。提取基因组DNA,并使用带有316芯片的Ion Torrent个人基因组机器(PGM)对相关基因进行NGS。将读取的序列与人参考HG19基因组进行比对,以阐明相关基因中的变异。通过PGM平台检测到的突变在第二个患者DNA样本上通过靶向直接桑格测序进行了确认。通过NGS总共在6个家族中鉴定出4个变异。其中,3个突变先前已有报道:相关基因的c.2126insA,以及相关基因的c.1310_1313delAAGA和c.7235insG。据我们所知,第四个变异,相关基因中的c.3453delT,此前从未有过报道。本研究首次将相关基因的NGS应用于摩洛哥人群,促使对该地区的本地奠基者突变和变异特征进行进一步研究。在进行靶向重测序时,没有明确临床意义的变异可能会带来诊断挑战。这些结果证实,基于扩增子文库和PGM测序的NGS方法是一种高效、快速且高通量的突变检测方法,在低收入国家可能更具优势。